<DOC>
	<DOCNO>NCT01319487</DOCNO>
	<brief_summary>The purpose study determine whether concentration FOV2304 ( high dose low dose ) administer eye effective placebo treat patient diabetic macular edema , follow 12 week treatment .</brief_summary>
	<brief_title>Safety Efficacy Study Topical Administration FOV2304 ( High Dose Low Dose ) Treatment Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Main inclusion/exclusion criterion list . Others may apply . 1 . Male female , least 18 year age . 2 . Diagnosis diabetes mellitus 3 . Patient must able self administer study drug . 4 . Clinically significant diabetic macular edema least one eye ( `` study eye '' ) involve center macula : 5 . Mild severe non proliferative diabetic retinopathy ( Early Treatment Diabetic Retinopathy Study [ ETDRS ] grade 20 53 ) . 6 . BCVA score â‰¥ 34 letter &lt; 80 letter study eye . 7 . Women childbearing potential must negative urine pregnancy test Screening use two highly effective method contraception throughout study . 8 . Male patient partner childbearing potential must agree use least one highly effective method contraception throughout study . Ocular condition : 1 . Any ocular condition study eye opinion investigator would prevent improvement visual acuity . 2 . Proliferative diabetic retinopathy study eye . 3 . History panretinal scatter photocoagulation ( PRP ) study eye within 4 month prior screen , and/or anticipate need PRP 3 month follow randomization . 4 . Active optic disc retinal neovascularization , rubeosis iridis , active history choroidal neovascularization study eye . 5 . History par plana vitrectomy time , intraocular surgery study eye within 90 day prior screen . 6 . History use intravitreal injectable periocular depot corticosteroid ( triamcinolone acetonide ) within 3 month prior screen visit study eye . 7 . Patients previously receive triamcinolone acetonide study eye : The intend dose triamcinolone acetonide injection 4 mg . The recent dose less 3 month prior screen visit . Any treatmentrelated adverse event see , opinion investigator , potential worsen reoccur study treatment . 8 . Patients previously receive antiVEGF therapy within 3 month prior screen visit study eye . 9 . Uncontrolled glaucoma glaucoma treat 2 medication . 10 . Aphakia intraocular lens placement anterior chamber study eye . 11 . Any active ocular infection ; history recurrent chronic infection inflammation study eye . 12 . History herpetic infection either eye . 13 . History corneal pathology/surgery 14 . Contact lens use time study . Systemic condition : 15 . Uncontrolled systemic disease . 16 . Poorly control diabetes mellitus . 17 . Impaired renal function 18 . Poorly control arterial hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>